CorWaves Next-Generation LVAD, Neptune, Receives Funding

The CALYPSO Research and Development (R&D) program, with a total budget
of 25 million euros over 4 years, will be partially financed with 14
million euros support from the Programme d’Investissements d’Avenir
(Future Investments Program), managed by the Secrétariat Général pour
l’Investissement (General Secretariat for Investment – SGPI) and
operated by Bpifrance.

A breakthrough technology addressing an important public health
issue: chronic heart failure.

here for the full news release.

The CALYPSO program aims to optimise and then clinically evaluate the
CorWave Neptune device, an implantable cardiac support blood pump
(Left Ventricular Assist Device or LVAD). Neptune features natural
physiological response, designed to reduce the risk of complications
associated to current LVADs and intended for patients suffering from
severe heart failure. Heart failure is involved in one in ten deaths in
France. This chronic disease can be fatal, with nearly half of patients
dying within five years of diagnosis. The number of patients affected by
heart failure increases as the population ages and becomes more

Louis de Lillers, CEO of CorWave, leader of the CALYPSO project: “We
are very pleased to set up major partnerships with world-class
university hospitals, thanks to the financial support of Bpifrance and
the French Government. The CALYPSO program considerably increases the
resources allocated to preclinical and clinical studies prior to the
marketing of Neptune, a cardiac support pump that closely mimics the
physiological flow of the native heart. This program will help CorWave
convert its disruptive technology into a sustainable competitive
advantage to establish itself as a global leader in cardiac support, a
market that already accounts for nearly $1 billion in annual sales.”

View source version on

Leave a Comment